GlassScriptPhysician profile
Odayme Quesada
NPI 1700143971
$32,429.23
in general payments reported to CMS, 2019-2025
16 companies · $8,443 in 2025
The $8,443 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $1,587 · 2022: $12K · 2023: $9,767 · 2024: $488 · 2025: $8,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Travel and Lodging: $5,724 · Food and Beverage: $2,263 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,211.25 |
| Travel and Lodging | $5,724.36 |
| Food and Beverage | $2,262.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,866.72 | 2022-2025 | Optis, Coroflow, Fielder |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7,797.20 | 2022-2025 | Lifevest |
| Genetesis, INC. | $7,344.96 | 2022-2023 | Cardioflux |
| Philips North America LLC | $2,969.33 | 2021-2025 | Peripheral Vascular Undivided, Igt Devices Undivided |
| Bayer Healthcare Pharmaceuticals INC. | $2,711.25 | 2025 | |
| Amgen INC. | $435.34 | 2022-2023 | Repatha |
| Novo Nordisk INC | $333.24 | 2023-2024 | |
| Heartflow, INC. | $208.73 | 2022 | |
| Medtronic, INC. | $145.74 | 2023 | Onyx Frontier |
| Kiniksa Pharmaceuticals International, Plc | $136.24 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2020 | |
| Zoll Circulation INC | $120.63 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $111.19 | 2023 | Camzyos |
| Cathworks, INC. | $75.21 | 2023 | Ffrangio |
| Novartis Pharmaceuticals Corporation | $48.45 | 2023-2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Odayme Quesada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.